Celgene Corporation reported un-audited consolidated earnings results for the fourth quarter and year ended December 31, 2016. For the quarter, the company reported total revenue increased 16% to $2,980.5 million from $2,563.3 million reported in last year. The company reported GAAP net income of $429 million and diluted earnings per share of $0.53 for the fourth quarter of 2016. For the fourth quarter of 2015, GAAP net income was $561.0 million and diluted EPS was $0.69. The decrease was primarily due to increased research and development (R&D) expenses as a result of the acquisition of Acetylon Pharmaceuticals Inc. and a fair value adjustment for an equity investment recorded in the fourth quarter of 2016. Adjusted net income for the fourth quarter of 2016 increased 34% to $1,290.1 million compared to $961.4 million in the fourth quarter of 2015. For the same period, adjusted diluted EPS increased 36% to $1.61 from $1.18. The company reported operating income of $929.9 million compared to $900.2 million and income before income taxes of $499.0 million compared to $745.5 million for the last year. Total revenue for the full-year of 2016 was $11,229.2 million, an increase of 21% year-over-year from $9,256.0 reported in last year. Full-year GAAP net income for 2016 was $1,999.2 million and diluted EPS was $2.49. Full-year GAAP net income for 2015 was $1,602 million and diluted EPS was $1.94. Adjusted net income for the full-year 2016 increased 23% to $4,770 million compared to $3,882.4 million reported in last year. Adjusted diluted EPS increased 26% to $5.94 from $4.71 for the full-year of 2015. The company reported operating income of $3,166.6 million compared to $2,254.6 million and income before income taxes of $2,372.5 million compared to $2,023.5 million for the last year.